Newly-diagnosed Pediatric T-cell ALL Protocol

The CCCG-T-ALL-2025 protocol will be modified as following based on the above analysis of the CCCG-ALL-2020 protocol. 1. All T-ALL patients will receive 8 mg/m2/day dexamethasone in induction therapy. 2. All non-ETP T-ALL patients will receive dasatinib after initial window phase in induction therapy. 3. non-ETP T-ALL patients with MRD ≥ 0.01% on day 46 will be stratified and randomized to receive different doses of homoharringtonine during early intensification. 4. For all ETP/near-ETP T-ALL patients, venetoclax will replace daunorubicin in induction therapy. 5. For all ETP/near-ETP T-ALL patients, venetoclax will replace daunorubicin in interim therapy 2 and 4. 6. CAT will replace CAT+ during early intensification, and will be administrated to all ETP/near-ETP patients, as well as non-ETP patients with MRD\< 0.01% on day 46. 2.11.7 In maintenance therapy 2, the CTX+Ara-C treatment cycles are reduced to 5, in order to minimize the impact of alkylating agents on fertility. 2.11.8 Add drug sensitivity testing for T-ALL.